Published • loading... • Updated
Ipsen completes acquisition of Kartos Therapeutics, strengthening late-stage Oncology pipeline
The acquisition adds navtemadlin, a Phase III add-on therapy that Ipsen says could improve outcomes for myelofibrosis patients with poor ruxolitinib response.
Summary by WBOC 16
7 Articles
7 Articles
The Toronto Star+5 Reposted by 5 other sources
Ipsen completes acquisition of Kartos Therapeutics, strengthening late-stage Oncology pipeline
PARIS, FRANCE, 21 AUGUST 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today it has completed the acquisition of Kartos Therapeutics, a clinical-stage biopharmaceutical company adding late-stage MDM2 inhibitor navtemadlin in Phase III clinical development in myelofibrosis.
·Toronto, Canada
Read Full Article
The laboratory pays 385 million euros for this specialist in hemato-oncology, but the shareholders of biotech could receive up to 1.3 billion additional dollars.
Coverage Details
Total News Sources7
Leaning Left3Leaning Right2Center1Last UpdatedBias Distribution50% Left
Bias Distribution
- 50% of the sources lean Left
50% Left
L 50%
C 17%
R 33%
Factuality
To view factuality data please Upgrade to Premium
